BCG TICE Vaccine ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 299 | Cystic fibrosis | 1 |
299. Cystic fibrosis
Clinical trials : 1,695 / Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04884308 (ClinicalTrials.gov) | April 28, 2021 | 7/5/2021 | Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections | Effects of BCG Vaccine on the Immune System of Individuals With Cystic Fibrosis, Non-Cystic Fibrosis Bronchiectasis, and Healthy Volunteers | Cystic Fibrosis;Bronchiectasis Adult;Non-Tuberculous Mycobacteria | Biological: BCG TICE Vaccine | Johns Hopkins University | Cystic Fibrosis Foundation | Recruiting | 18 Years | 65 Years | All | 180 | Phase 2 | United States |